Arrowhead Pharmaceuticals announced FDA acceptance of its New Drug Application for plozasiran to treat familial chylomicronemia syndrome (FCS), with a PDUFA date of November 18, 2025.
Arrowhead Pharmaceuticals is advancing two RNAi-based therapies, ARO-INHBE and ARO-ALK7, into clinical trials for obesity treatment, targeting novel mechanisms of action.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.